JPWO2021245499A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021245499A5 JPWO2021245499A5 JP2022574452A JP2022574452A JPWO2021245499A5 JP WO2021245499 A5 JPWO2021245499 A5 JP WO2021245499A5 JP 2022574452 A JP2022574452 A JP 2022574452A JP 2022574452 A JP2022574452 A JP 2022574452A JP WO2021245499 A5 JPWO2021245499 A5 JP WO2021245499A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- formula
- composition
- carbonyl group
- carbonyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN202041023434 | 2020-06-04 | ||
| IN202041023434 | 2020-06-04 | ||
| PCT/IB2021/054591 WO2021245499A1 (en) | 2020-06-04 | 2021-05-26 | Novel small molecules for targeted degradation of untargetable kras in cancer therapy |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2023529354A JP2023529354A (ja) | 2023-07-10 |
| JP2023529354A5 JP2023529354A5 (https=) | 2024-06-03 |
| JPWO2021245499A5 true JPWO2021245499A5 (https=) | 2024-06-03 |
| JP7789016B2 JP7789016B2 (ja) | 2025-12-19 |
Family
ID=78830675
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022574452A Active JP7789016B2 (ja) | 2020-06-04 | 2021-05-26 | 癌治療における標的化不能ｋｒａの標的分解のための新規の小分子 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230202981A1 (https=) |
| EP (1) | EP4161511B1 (https=) |
| JP (1) | JP7789016B2 (https=) |
| KR (1) | KR20230019937A (https=) |
| CN (2) | CN120208921A (https=) |
| AU (1) | AU2021284517A1 (https=) |
| BR (1) | BR112022024300A2 (https=) |
| CA (1) | CA3180686A1 (https=) |
| IL (1) | IL298672A (https=) |
| MX (1) | MX2022015253A (https=) |
| WO (1) | WO2021245499A1 (https=) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11932633B2 (en) | 2018-05-07 | 2024-03-19 | Mirati Therapeutics, Inc. | KRas G12C inhibitors |
| WO2020055761A1 (en) | 2018-09-10 | 2020-03-19 | Mirati Therapeutics, Inc. | Combination therapies |
| CA3112043A1 (en) | 2018-09-10 | 2020-03-19 | Mirati Therapeutics, Inc. | Combination therapies |
| SMT202500028T1 (it) | 2018-09-10 | 2025-03-12 | Mirati Therapeutics Inc | Terapie combinate |
| JP2022500385A (ja) | 2018-09-10 | 2022-01-04 | ミラティ セラピューティクス， インコーポレイテッド | 組み合わせ療法 |
| CN113164418A (zh) | 2018-12-05 | 2021-07-23 | 米拉蒂治疗股份有限公司 | 组合疗法 |
| WO2020146613A1 (en) | 2019-01-10 | 2020-07-16 | Mirati Therapeutics, Inc. | Kras g12c inhibitors |
| WO2021041671A1 (en) | 2019-08-29 | 2021-03-04 | Mirati Therapeutics, Inc. | Kras g12d inhibitors |
| CN114761012B (zh) | 2019-09-24 | 2025-03-21 | 米拉蒂治疗股份有限公司 | 组合疗法 |
| PH12022551513A1 (en) | 2019-12-20 | 2023-04-24 | Mirati Therapeutics Inc | Sos1 inhibitors |
| WO2022056307A1 (en) | 2020-09-11 | 2022-03-17 | Mirati Therapeutics, Inc. | Crystalline forms of a kras g12c inhibitor |
| WO2022132200A1 (en) | 2020-12-15 | 2022-06-23 | Mirati Therapeutics, Inc. | Azaquinazoline pan-kras inhibitors |
| EP4262803A4 (en) | 2020-12-16 | 2025-03-12 | Mirati Therapeutics, Inc. | Tetrahydropyridopyrimidine pan-kras inhibitors |
| WO2025083570A1 (en) * | 2023-10-18 | 2025-04-24 | Pillai Universal Llc | Novel small-molecule agents in overcoming tumor regression in cancers |
| WO2025083568A1 (en) * | 2023-10-18 | 2025-04-24 | Pillai Universal Llc | Novel small-molecule protein kinase inhibitors for implications in cancer treatment |
| WO2025083563A1 (en) * | 2023-10-18 | 2025-04-24 | Pillai Universal Llc | Effective therapeutic small-molecule inhibitors for metastatic cancer |
| WO2025083564A1 (en) * | 2023-10-18 | 2025-04-24 | Pillai Universal Llc | Novel small molecule degrader as a potential anticancer |
| WO2025083561A1 (en) * | 2023-10-18 | 2025-04-24 | Pillai Universal Llc | Novel lead small molecule inhibitors on undruggable target towards anticancer activity |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0012362D0 (en) * | 2000-05-22 | 2000-07-12 | Aventis Pharma Ltd | Chemical compounds |
| DZ3347A1 (fr) * | 2000-05-22 | 2001-11-29 | Aventis Pharma Inc | Dérivés d'arylméthylamine pour leur utilisation comme inhibiteurs de la tryptase |
| MXPA04004178A (es) * | 2001-11-01 | 2004-09-06 | Janssen Pharmaceutica Nv | Heteroarilaminas como inhibidores de glucogeno cintasa cinasa 3beta. |
| WO2007075896A2 (en) * | 2005-12-22 | 2007-07-05 | Kemia, Inc. | Heterocyclic cytokine inhibitors |
| AU2011239537A1 (en) * | 2010-04-16 | 2012-11-15 | Curis, Inc. | Treatment of cancers having K-ras mutations |
| US20190284149A1 (en) * | 2014-09-12 | 2019-09-19 | Ariagen, Inc. | Aryl hydrocarbon receptor modulator |
| CN106317055A (zh) * | 2015-07-02 | 2017-01-11 | 中国科学院上海药物研究所 | 一类具有激酶抑制活性的化合物、制备方法和用途 |
| WO2018140513A1 (en) * | 2017-01-26 | 2018-08-02 | Araxes Pharma Llc | 1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1yl)prop-2-en-1-one derivatives and similar compounds as kras g12c modulators for treating cancer |
| CN110885332B (zh) * | 2019-12-06 | 2022-03-18 | 中国人民解放军第二军医大学 | 一种PDEδ蛋白降解靶向嵌合体及其制备方法和应用 |
-
2021
- 2021-05-26 MX MX2022015253A patent/MX2022015253A/es unknown
- 2021-05-26 BR BR112022024300A patent/BR112022024300A2/pt unknown
- 2021-05-26 IL IL298672A patent/IL298672A/en unknown
- 2021-05-26 CA CA3180686A patent/CA3180686A1/en active Pending
- 2021-05-26 US US18/008,332 patent/US20230202981A1/en active Pending
- 2021-05-26 KR KR1020237000112A patent/KR20230019937A/ko active Pending
- 2021-05-26 AU AU2021284517A patent/AU2021284517A1/en active Pending
- 2021-05-26 CN CN202510275737.2A patent/CN120208921A/zh active Pending
- 2021-05-26 EP EP21817859.8A patent/EP4161511B1/en active Active
- 2021-05-26 JP JP2022574452A patent/JP7789016B2/ja active Active
- 2021-05-26 WO PCT/IB2021/054591 patent/WO2021245499A1/en not_active Ceased
- 2021-05-26 CN CN202180049321.9A patent/CN115768427B/zh active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPWO2021245499A5 (https=) | ||
| JP6657182B2 (ja) | 癌治療用のｃｄ７３阻害剤としてのプリン誘導体 | |
| MX2022015253A (es) | Moleculas peque?as novedosas para la degradacion dirigida de kras no dirigibles en la terapia contra el cancer. | |
| KR101758400B1 (ko) | 종양성 또는 자가면역 질환 치료용 전구약물로서의 푸라자노벤즈이미다졸 | |
| AU2019203282A1 (en) | Dipeptide and tripeptide epoxy ketone protease inhibitors | |
| JP2011509309A5 (https=) | ||
| JP2015524457A5 (https=) | ||
| CA2537127A1 (en) | Benzimidazolone compounds having 5-ht4 receptor agonistic activity | |
| JP2006508970A5 (https=) | ||
| WO2016104617A1 (ja) | キノリン誘導体 | |
| JP2021530487A5 (https=) | ||
| JP2020517707A5 (https=) | ||
| CN102574837A (zh) | 新的5-氟尿嘧啶衍生物 | |
| JP2009538910A5 (https=) | ||
| JP2007527919A5 (https=) | ||
| CN105473573A (zh) | 用作激酶抑制剂的咔唑甲酰胺化合物 | |
| JP2013542267A5 (https=) | ||
| JP2020128426A5 (https=) | ||
| JP2011517697A5 (https=) | ||
| TW201712004A (zh) | 吡唑衍生物或其藥理學上容許之鹽 | |
| KR20190141133A (ko) | 열 충격 단백질 90 억제제 | |
| TWI829329B (zh) | 組蛋白去乙醯化酶6和熱休克蛋白90之雙重抑制劑 | |
| JPWO2019236890A5 (https=) | ||
| JP7416757B2 (ja) | 置換テトラヒドロシクロペンタ［ｃ］ピロール、置換ジヒドロピロリジン、その類似体、およびそれらを使用する方法 | |
| WO2015189265A1 (en) | Small molecule lfa-1 inhibitors |